Compositions and methods for weight loss in at risk patient populations

摘要

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

主权项

1. A method of treating a subject for overweight or obesity, comprising:
selecting for treatment an overweight or obese subject at increased risk of a major adverse cardiovascular event that has had type-two diabetes for a period of less than 6 years; and treating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of sustained release naltrexone, or a pharmaceutically acceptable salt thereof and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks, wherein said administering reduces the risk of a major adverse cardiovascular event in said overweight or obese subject.